We read with interest the correspondence by Xiao et al. in The Lancet Gastroenterology & Hepatology discussing the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with decompensated cirrhosis.1 We have reviewed the available literature (published in PubMed, EMBASE, and Web of Science up to April 13, 2020) for potential mechanisms that would place cirrhotic patients at increased susceptibility to COVID-19 infection.
|Titolo:||ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis|
TARGHER, Giovanni [Writing – Review & Editing]
|Data di pubblicazione:||2020|
|Appare nelle tipologie:||01.01 Articolo in Rivista|